ES3036928T3 - Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies - Google Patents

Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Info

Publication number
ES3036928T3
ES3036928T3 ES20901160T ES20901160T ES3036928T3 ES 3036928 T3 ES3036928 T3 ES 3036928T3 ES 20901160 T ES20901160 T ES 20901160T ES 20901160 T ES20901160 T ES 20901160T ES 3036928 T3 ES3036928 T3 ES 3036928T3
Authority
ES
Spain
Prior art keywords
gdnf
pharmaceutical composition
colon
mice
hscr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20901160T
Other languages
English (en)
Spanish (es)
Inventor
Rodolphe Soret
Nicolas Pilon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Application granted granted Critical
Publication of ES3036928T3 publication Critical patent/ES3036928T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES20901160T 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies Active ES3036928T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950781P 2019-12-19 2019-12-19
PCT/CA2020/051746 WO2021119827A1 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Publications (1)

Publication Number Publication Date
ES3036928T3 true ES3036928T3 (en) 2025-09-25

Family

ID=76476522

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20901160T Active ES3036928T3 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Country Status (6)

Country Link
US (1) US20230022970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076499B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665215B2 (cg-RX-API-DMAC7.html)
CA (1) CA3162011A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036928T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021119827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240366723A1 (en) * 2021-06-16 2024-11-07 Transfert Plus, Limited Partnership Combination therapy for the treatment of enteric neuropathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
EP3414322A4 (en) * 2015-12-23 2020-03-04 Memorial Sloan-Kettering Cancer Center CELL THERAPY AND DRUG DISCOVERY BASED ON CELL LINES DERIVED FROM HUMAN ENTERAL NEURAL CREST DERIVED FROM PLURIPOTENT STEM CELLS

Also Published As

Publication number Publication date
EP4076499A4 (en) 2023-11-01
EP4076499B1 (en) 2025-07-16
JP7665215B2 (ja) 2025-04-21
EP4076499A1 (en) 2022-10-26
JP2023515915A (ja) 2023-04-17
EP4076499C0 (en) 2025-07-16
US20230022970A1 (en) 2023-01-26
WO2021119827A1 (en) 2021-06-24
CA3162011A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7696406B2 (ja) 細胞加齢の反転のための一過性細胞リプログラミング
US20130295015A1 (en) Optically-Controlled CNS Dysfunction
ES2351957T3 (es) Pax2 para tratar trastornos del riñón.
ES3036928T3 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
Mohammad et al. Functional compensation between cholecystokinin-1 and-2 receptors in murine paraventricular nucleus neurons
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
ES2322881B1 (es) Uso de compuestos agonistas de la actividad pi3k en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas.
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
ES2374729T3 (es) Inhibición de la diferenciación de células madre, aumento de la proliferación e inducción selectiva de la apoptosis por factores wnt.
RU2801316C2 (ru) Транзиентное клеточное перепрограммирование для обращения старения клетки
Sewell Determining the Role of Beta-Tubulin 4b in Cilia and Development
Souchkova et al. A MOLECULAR-BASED REGENERATIVE MEDICINE APPROACH FOR THE TREATMENT OF HIRSCHSPRUNG DISEAS
Lazzeri-Barcelo Studies on obesity-related dysfunction in insulin-target tissues: insulin receptor isoforms and intraocular in vivo liver imaging
Krishna Chandran MÜLLER GLIAL CELLS IN EPIRETINAL MEMBRANE FORMATION
Calovi STUDY OF THE EFFECT OF P2X7 RECEPTOR PROTEIN FUNCTIONAL EXPRESSION IN THE PHENCYCLIDINE MURINE MODELS FOR SCHIZOPHRENIA
Vidarsson Foxi1, an important gene for hearing, kidney function and male fertility
Kociaj The role of neural stem/progenitor cells in mediating the functional recovery of adult zebrafish brain after traumatic injury
MacLean ATP elicits electrophysiological and migratory responses in cells of the spinal cord stem cell niche
Shahid Functional compensation among metabotropic receptors involved in cytosolic Ca^< 2+> signaling and satiety control mechanisms
Lecture Scientific Programme Committee
Yung Functional characterization of Netrin-1 and its role in CNS-PNS boundary maintenance in the developing vertebrate brainstem
Carstens Perineuronal Nets in Hippocampal Area CA2: Regulation by Activity and Disease
Kosse Functional properties of GAD65 neurons in the lateral hypothalamus
HONG et al. Combined Zinc plus N-acetyl-L-cysteine supplement increases adult hippocampal
Oscar-Berman et al. Welcome to the Twentieth Annual Henry I. Russek Student Achievement Day!